Immunosuppressant drugs, such as methotrexate, are able to inhibit cytokine production and leukocyte migration to inflammatory foci; therefore, they could modify the establishment of inflammation in adipose tissue during obesity. Thus, we studied the effects of methotrexate in vivo on high-fat diet inducedobesity in mice and in vitro in isolated and co-cultured adipocytes and macrophages. Obese mice treated with methotrexate presented reduced serum levels of TNF-a, insulin and glucose, and an improvement of insulin sensitivity. Adipose tissue from these mice produced less proinflammatory (TNF-a, IL-6, leptin) and more anti-inflammatory adipokines (adiponectin and IL-10) associated with reduced macrophage infiltration and inflammation. Cytokine inhibition was also confirmed in isolated and co-cultured adipocytes and macrophages. Methotrexate presented anti-lipolytic effect in vivo and, in vitro through adenosine release. Drugs that combine anti-lipolytic effect and the ability to control inflammation in adipose tissue could play a role in the control of insulin resistance and other pathologies associated with obesity.
Introduction
Adipose tissue is an important source of inflammatory mediators, such as TNF-a, IL-6 and leptin, during obesity. The levels of these adipokines are increased in plasma, characterizing a chronic low-grade systemic inflammation and contributing to the development of many aspects of metabolic syndrome and type 2 diabetes. Adipose tissue inflammation characterized by inflammatory mediator production is associated with increased infiltration of macrophages and other inflammatory cells in adipose tissue (Zeyda and Stulnig, 2007) .
Several anti-inflammatory and immunosuppressant drugs are able to inhibit cytokine production and inflammatory cell migration, therefore they could play a role in adipose tissue inflammation control or at least, they could work as important tools to study the immune participation in the obesity-associated pathologies.
Several publications have demonstrated that the blockade of TNF-a using etanercept in patients with metabolic syndrome resulted in improvements in inflammatory markers without modifications to insulin sensitivity (Bernstein et al., 2006) ; the classical COX-2 inhibitors nimesulide and celecoxib were able to reduce the development of inflammatory responses in adipose tissues of high-fat-induced obese rats resulting in improved of glucose tolerance (Hsieh et al., 2010) ; in obese humans, low-dose aspirin inhibited systemic IL-6 and reduced IL-6 release from subcutaneous adipose tissue (Ogston et al., 2008) .
Methotrexate is a disease-modifying anti-arthritic drug that acts as a folic acid antagonist, blocking the synthesis of purines and pyrimidines by inhibiting several key enzymes (Genestier et al., 2000) . This mechanism of action seems to be responsible for many side effects of this drug, which are minimized by folic acid or folinic acid administration (Dijkmans, 1995) . Additional pharmacological mechanisms are described for methotrexate, such as suppression of transmethylation reactions, reduction of antigendependent T-cell proliferation, and promotion of adenosine release (Tian et al., 2007) . Methotrexate is able to reduce leukocyte accumulation at the inflammatory site, and this action seems to be dependent of adenosine A2A receptor (Montesinos et al., 2006 ). The drug is also able to inhibit TNF-a production during inflammatory response in wild-type but not in A(2A) or A(3) receptor knockout mice (Montesinos et al., 2003) . IL-6 production is also inhibited by methotrexate (Sung et al., 2000) , suggesting that methotrexate can also modify several inflammatory parameters associated with obesity. Additionally, A1 adenosine receptor is expressed in adipose tissue (Tatsis-Kotsidis and Erlanger, 1999) and seems to inhibit lipolysis (Johansson et al., 2008) . Drugs that reduce free fatty acids release from adipose tissue could have a role in insulin resistance (Dhalla et al., 2009) .
Thus, we studied the methotrexate action upon systemic and adipose tissue inflammation associated with obesity in mice fed with high-fat diet. We also studied in vitro methotrexate action on lipolysis and cytokine production in isolated cells and adipocyte/macrophage co-culture system.
Materials and methods

Animals
Six-week-old Swiss strain male mice, free of specific pathogens, were obtained from CEMIB (State University of Campinas, Campinas, SP, Brazil). Experiments were performed in accordance with the principles outlined by the Brazilian College for Animal Experimentation (COBEA) and received approval from the Ethics Committee of São Francisco University, Bragança Paulista, SP, Brazil (Protocol 1/2008). Animals were maintained on a 12:12 h artificial light-dark cycle and housed individually.
Diet-induced obesity and methotrexate treatment
After random selection, mice were introduced to control (15% energy from fat) or high-fat diets (HFD; 60% energy from fat) ( Table  1; Pinto et al., 2010) . Body weights were assessed weekly. After 10 weeks, the high-fat diet animals were randomly divided into three groups. During the next two weeks, the first group received 2 mgkg À1 of methotrexate per week (intraperitoneally -i.p., divided into two administrations; Sigma, St. Louis, MO, USA); the second group received 4 mg kg À1 of methotrexate per week (i.p., divided in two administrations), and the last group received only saline (HFD group) at same volume and administration route. During methotrexate treatment, food intake was recorded.
Blood glucose levels and insulin tolerance tests
After 6 h of fasting, the mice were anesthetized (i.p., 0.1 ml/50 g of body weight of 1:1 v/v xylasine 2%/ketamine 10%) and blood samples were collected from their tails. Glucose was measured using the glucose oxidase method. Insulin (1.5 U/kg) was administered by an i.p. injection, and blood samples were collected for serum glucose determination at 0, 10, 15, 20 and 30 min. The rate constant for glucose disappearance during an insulin tolerance test (KITT) was calculated using the formula 0.693/t1/2. The glucose t1/ 2 was calculated from the slope of the least square analysis of plasma glucose concentrations during the linear decay phase. The test was performed at the end of methotrexate treatment.
Necropsy
Mice were deprived of food for 6 h and were anesthetized. Blood samples were collected by cardiac puncture and used to isolate serum for analyses. Epididymal and perirenal adipose tissues were carefully dissected, weighed and employed for subsequent analysis.
2.5. Determination of cytokines, insulin level and lipid profile in serum Serum levels of TNF-a, IL-6 and IL-10 were determined using ELISA kits (R&D Systems, MN, USA). Insulin measurement in serum was performed using ELISA kit from ALPCO (Salem, NH, USA). Plasma concentrations of total cholesterol (CHOL), high-and lowdensity lipoprotein cholesterol, triglyceride were determined using the Cobas-Mira System (Roche Diagnostics, Indianapolis, IN, USA).
Adipose tissue histology and immunohistochemistry
Hydrated, 5.0-lm sections of paraformaldehyde-fixed, paraffinembedded adipose tissue specimens were probed with anti-rabbit F4/80 (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by biotinylated anti-rabbit secondary antibody and developed with DAB (kit ABC -Santa Cruz Biotechnology). Hematoxylin was used to stain nuclei morphology. For each group, adipose tissues from five animals were prepared and stained. Slides were analyzed using an optical microscope (Eclipse DS50, Nikon Inc., Osaka, Japan) at a final magnification of 200Â. Photomicrographs were analyzed using NIS-Elements software (Nikon Inc., Osaka, Japan) to quantify the presence of brownish-color immunostaining.
Short-term culture of adipose tissue
Biopsies from epididymal adipose tissue were minced and incubated with constant shaking (60 cycles/min) for 4 h at 37°C in a 5% CO 2 atmosphere with Medium 199 (Gibco, Gaithersburg, MD, USA) supplemented with 1% bovine serum albumin. Secretion of adipocytokines was evaluated by measuring the amount of adipocytokines released from white adipose tissue (WAT) cells into the incubation media without any stimulus, using commercial EIA kits (TNF-a, IL-6 and IL-10 from R&D Systems; Leptin and Adiponectin from BBridge International, Mountain View, CA, USA). Basal lipolysis was evaluated by measuring glycerol released in the incubation media without any stimulus using a commercial kit (Laborlab, SP, Brazil).
Protein extraction and western blot analysis
For evaluation of protein expression, adipose tissue fragments were homogenized in solubilizing buffer at 4°C [1% Triton X-100, 100 mM Tris-HCl (pH 7.4), 100 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM sodium orthovanadate, 2.0 mM PMSF and 0.1 mg aprotinin/ml]. Insoluble material was removed by centrifugation for 20 min at 9000 g at 4°C. The protein concentrations of the supernatants were determined by the Biuret method. Extracts were treated with Laemmli sample buffer containing 100 mM dithiothreitol and heated in a boiling water bath for 5 min, after which time they were subjected to SDS-PAGE in a Bio-Rad miniature slab gel apparatus (Mini-Protean). For immunoblot experiments, 0.1 mg of protein extracts from each tissue were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with anti-MCP-1, anti-JNK, anti-p-JNK, anti-iNOS and anti-b-actin (Santa Cruz Biotechnology). Nitrocellulose membranes were developed using commercial chemiluminescent kits (GE Healthcare, UK). Band intensities were quantitated by optical densitometry using ImageQuant 350 (GE Healthcare, UK). 2.9. Cell culture and co-culture system 3T3-L1 preadipocytes were obtained from the ATCC and maintained in DMEM containing 10% fetal bovine serum (Gibco BRL, NY, USA). The 3T3-L1 were plated in 24-well plates and cultured until confluency. Differentiation was induced by the addition of DMEM supplemented with 1 lM dexamethasone, 0.5 mM isobutylmethylxanthine, 10 lg/ml insulin and 10% fetal bovine serum for 3 days and followed by the addition of DMEM supplemented with 10 lg/ml of insulin and 10% fetal bovine serum for another 10 days. Murine macrophage cell line RAW 264.7 was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gibco BRL, NY, USA) and placed in 0.45 lM culture inserts (Millipore, Ireland). Culture inserts were placed in wells containing 3T3-L1 mature adipocytes. Stimulus or drugs were added to the insert compartment, and after 48 h, the culture medium was collected from both compartments. Isolated mature adipocytes were also assayed for lipolytic activity by measuring glycerol in the culture supernatant using a commercial kit (Laborlab).
Statistical analysis
Data are expressed as the mean ± S.E.M. Comparisons among groups of data were made using one-way ANOVA followed by the Dunnett Multiple Comparisons test. An associated probability (P value) of less than 5% was considered significant.
Results
Body weight, adiposity and metabolic status
Mice fed with HFD presented high body weight and adiposity evaluated by measurements of two adipose tissue depots at the end of 12 weeks in comparison to mice fed a normal diet (Table  2) . MTX treatment did not reduce body weight, adiposity or lipid profile in both doses used (Table 2) . Food intake was also not modified by MTX treatment. However, alterations in basal glucose levels and response to insulin administration observed in HFD mice were reversed by MTX treatment (Table 2 ). Serum levels of insulin tended to be lower in HFD mice treated with MTX at 4 mg/kg/week (p = 0.07). The serum TNF-a level was also decreased in MTX-treated mice, while the serum IL-6 and IL-10 levels were not altered (Table 2 ). Mice fed with normal diet treated with MTX presented no alterations in body weight (41.3 ± 2.1, 45.0 ± 3.5 and 42.7 ± 2.8 g for control and treated with 2 or 4 mg/kg/week, respectively), adiposity (1.7 ± 0.2, 1.8 ± 0.3 and 1.9 ± 0.1% of body weight from epididymal fat for control and treated with 2 or 4 mg/kg/week, respectively), lipid profile (data not shown), basal glucose levels (121 ± 3, 130 ± 6 and 152 ± 21 mg/dl of glucose for control and treated with 2 or 4 mg/kg/week, respectively) or serum insulin levels (0.4 ± 0.1, 0.5 ± 0.1 and 0.4 ± 0.1 ng/ml for control and treated with 2 or 4 mg/kg/week, respectively).
Adipose tissue inflammation
Visceral (epididymal) adipose tissue from mice fed with HFD released high amounts of TNF-a and leptin in short-term culture and low amounts of adiponectin when compared with visceral adipose tissue from mice fed with normal diet (Table 3) . Visceral adipose tissue from mice treated with 4 mg/kg of MTX released less TNF-a and leptin than HFD mice (Table 3) . Adiponectin production was reestablished at levels similar to those observed in control mice for both MTX groups (Table 3) . Interestingly, anti-inflammatory IL-10 levels were also increased in adipose tissue in mice treated with 4 mg/kg MTX. Macrophage infiltration was evaluated by immunohistochemistry analysis of F4/80 + cells. HFD mice presented a prominent macrophage infiltration in epididymal adipose tissue, whereas MTX-treated mice did not (Fig. 1) . Additional inflammatory markers were evaluated by western blot analysis, such as MCP-1, iNOS and JNK phosphorylation. MCP-1 and iNOS protein levels were increased in epididymal adipose tissue from HFD mice and were reduced after MTX treatment for both doses ( Fig. 2A and B) . Analysis of JNK phosphorylation revealed that only mice treated with 4 mg/kg of MTX presented a reduction of JNK activation (Fig. 2C ).
Lipolytic activity ex vivo and in vitro
Basal lipolysis was evaluated ex vivo after short-term culture of adipose tissue from mice. Adipose tissue from HFD mice presented higher lipolytic activity when compared with adipose tissue from mice fed with normal diet (Fig. 3A) . Adipose tissue from MTX-treated mice (4 mg/kg) released glycerol at the same level as control mice (Fig. 3A) . In vitro, 3T3-L1 mature adipocytes spontaneously released reduced amounts of glycerol in the presence of MTX. Table 2 Clinical and cytokine serum parameters for control, high-fat diet (HFD) and methotrexate (MTX)-treated mice (MTX2 and MTX4 for 2 or 4 mg/kg/week, respectively).
Control
HFD MTX 2 MTX 4
Final body weight 41.8 ± 1.3 53.9 ± 2.4 ** 53.0 ± 2.5 55.5 ± 1.6 Epididymal fat (% body weight)
1.4 ± 0.2 2.1 ± 0.1 * 1.9 ± 0.2 2.5 ± 0.2 Perirenal fat (% body weight) 0.18 ± 0.09 0.40 ± 0.10 0.32 ± 0.07 0.27 ± 0.01 Food Intake (g/day)
3.6 ± 0.1 2.5 ± 0.4 2.1 ± 0.1 2.3 ± 0.2 Caloric intake (kcal/day) 14.1 ± 0.4 13.5 ± 2.3 10.9 ± 0.7 12.3 ± 0.9 Basal glucose (mg/dl) 197 ± 11 285 ± 16 41.4 ± 6.7 IL-10 (ng/ml) 8.9 ± 3.2 12.8 ± 1.7 8.7 ± 2.9 6.8 ± 2.1 * p < 0.05 when comparing HFD versus control group (n = 6). ** p < 0.01 when comparing HFD versus control group (n = 6). # p < 0.05 when comparing MTX-treated versus HFD group (n = 6). ## p < 0.01 when comparing MTX-treated versus HFD group (n = 6).
+ p = 0.07 when comparing MTX-treated versus HFD group (n = 6).
We used this assay to define the MTX anti-lipolytic dose and to study whether adenosine receptor had a role in lipolytic activity (Fig. 3B ). For this proposal, DPCPX, an agonist of adenosine A1 receptor, was added to adipocyte culture before MTX treatment. DPCPX was able to reverse the anti-lipolytic effect of MTX in the adipocyte culture (Fig. 3B) . Co-culture experiments demonstrated that macrophages in contact with adipocytes also activated lipolysis (Fig. 3C ). MTX treatment was also able to inhibit lipolysis, and DPCPX was able to inhibit the anti-lipolytic MTX effect (Fig. 3C) .
Macrophage/Adipocyte co-culture model of adipose tissue inflammation
When adipocytes were cultured with macrophages, an increased cytokine production was observed (Fig. 4A and B) . The same profile was observed when individual cell lines or co-cultured cells were stimulated with LPS ( Fig. 4A and B) . MTX was not able to inhibit basal TNF-a or IL-6 production in isolated or in co-culture system, but it was effective in reducing LPS-stimulated TNF-a and IL-6 levels in Table 3 Adipokines release by epididymal adipose tissue for control, high-fat diet (HFD) and methotrexate (MTX)-treated mice (MTX2 and MTX4 for 2 or 4 mg/kg/week, respectively). adipocytes and macrophages co-cultures, as well as in LPS-stimulated TNF-a and IL-6 in isolated macrophages culture (Fig. 4A and  B) . IL-6 production after LPS stimulus was also inhibited in isolated adipocyte culture (Fig. 4A) .
Control
Discussion
Obesity is associated with a chronic low-grade inflammatory state described as a predominant proinflammatory cytokine production by adipose tissue related to a prominent infiltration of inflammatory cells. Adipokines produced by adipose tissue, i.e., TNF-a and IL-6, may act as very deleterious mediators in insulin sensitivity and additionally down regulate the expression of antiinflammatory adipokines such as adiponectin (Hotamisligil et al., 1993; Eder et al., 2009; Hajri et al., 2011) . Anti-inflammatory, immunosuppressant or disease-modifying drugs could inhibit the adipokine production and therefore modify the onset of insulin resistance associated with adiposity. In our study, mice fed with HFD and treated with MTX did not exhibit the altered adiposity but rather presented low levels of serum TNF-a and adipose tissue TNF-a and IL-6. This inhibition was accompanied by modifications mainly in local adipokine production, resulting in high levels of adiponectin and IL-10 release. In these mice, basal glucose, insulin and response to insulin administration were improved despite obesity. MTX doses employed in our protocol (2 and 4 mg/kg/ week) did not exhibit hepatic toxicity, assessed by steatosis area measurement and TBARs production in liver samples (data not shown). Changes in the adipokine profile produced by visceral adipose tissue were related to an observed reduction of macrophage infiltration. Analysis of adipocytes and macrophages from obese mice and humans showed that macrophages produced almost all the TNF-a and an equal amount of IL-6 when compared to adipocytes (Weisberg et al., 2003) . Local interactions between macrophage and adipocytes could have an important role in deregulating adipocyte physiology and adipokine production contributing to systemic insulin resistance (Suganami et al., 2005) . Macrophage recruitment by adipose tissue seems to be dependent of monocyte chemoattractant protein-1 (MCP-1) (Surmi and Hasty, 2010) . Studies with knockout mice for MCP-1 presented contradictory results in terms of improved insulin sensitivity (Surmi and Hasty, 2010) . After MTX treatment, we observed reduced levels of MCP-1 expression in adipose tissue, but this reduction could be related to inhibition of macrophage infiltration because macrophages also contribute to MCP-1 adipose tissue production and recruitment of additional macrophages. Macrophages treated with MTX, isolated or in contact with adipocytes (co-culture), produced less amounts of TNF-a and IL-6, suggesting a direct effect of MTX. This effect suggests a role in downregulation of proinflammatory cytokine as well as chemokine production, resulting in an interruption of deleterious adipocyte interaction and attraction of more macrophages. In agreement with the idea that TNF-a blockade could account for the reestablishment of adiponectin production, we also observed that the level of JNK phosphorylation in MTXtreated adipose tissue was reduced. JNK activation is described as an important signaling molecule in TNF-a-mediated adiponectin suppression in adipocytes (Kim et al., 2005) .
Inducible nitric oxide synthase (iNOS) induction was associated with insulin resistance at the S-nitrosylation of insulin receptor subunit beta and Akt impairs insulin signaling (Carvalho-Filho et al., 2006) . Macrophages recruited to adipose tissue during inflammation up-regulated iNOS (Lumeng et al., 2007) ; iNOS is up-regulated in several inflammatory conditions and iNOS inhibition seems to promote an anti-inflammatory action. MTX was not effective in inhibiting iNOS expression or nitric oxide production in murine J774 macrophages (Hämäläinen et al., 2002) , suggesting that inhibition of iNOS expression observed in our results could be due to a reduction of infiltrating macrophages or a consequence of an indirect MTX effect.
Finally, another interesting MTX action observed in this study was its anti-lipolytic effect. Ex vivo epididymal adipose tissue from MTX-treated mice released less amounts of glycerol when cultured. In vitro isolated 3T3-L1 adipocytes or adipocytes co-cultured with macrophages also released less glycerol when incubated with MTX. One of the actions described for MTX is the promotion of adenosine release, which may explain these observations. Adenosine is considered to be an important endogenous anti-lipolytic factor, and there is evidence to suggest that the receptor responsible for this effect is the adenosine A1 receptor (Fatholahi et al., 2006; Johansson et al., 2008) . In fact, the anti-lipolytic MTX effect was reversed in vitro by DPCPX, a selective antagonist of adenosine A1 receptor, supporting the hypothesis that MTX also possesses an anti-lipolytic effect mediated through adenosine release. The antilipolytic effect associated with the ability to control inflammation in the adipose tissue could explain the reversal of insulin resistance despite the presence of adiposity. Thus, drugs that combine these actions should be explored, which could have a role in the management of obesity associated pathologies.
